среда, 18 мая 2016 г.

Novartis Splits Up Drug Unit as Top Executive Will Depart

Novartis Splits Up Drug Unit as Top Executive Will Depart


Novartis AG will reorganize its operations to create separate units for cancer and for other drugs, underscoring the Swiss company's focus on oncology following the purchase of assets last year from GlaxoSmithKline Plc. Following the changes, the Basel-based drugmaker's head of pharmaceuticals, David Epstein, will leave the company.



from Biotech News